Antigenic maps of influenza A(H3N2) produced with human antisera obtained after primary infection

Journal of Infectious Diseases

Volumn 213, Issue 1, 2016, Pages 31-38

  Fonville, Judith M ^a,b,c   Fraaij, Pieter L A ^c,d   De Mutsert, Gerrie ^c   Wilks, Samuel H ^a,b   Van Beek, Ruud ^c   Fouchier, Ron A M ^c   Rimmelzwaan, Guus F ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b and Control of Emerging Infectious Diseases   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

primary infection; influenza; human antisera; antigenic cartography; antibody landscapes

Indexed keywords

VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY TITER; ARTICLE; BIRD DISEASE; CHILD; CONTROLLED STUDY; FERRET; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); NONHUMAN; PRESCHOOL CHILD; PRIMARY INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; VIRUS CHARACTERIZATION; VIRUS ISOLATION; ANIMAL; BLOOD; DISEASE MODEL; IMMUNOLOGY; INFANT; INFLUENZA;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; RETROSPECTIVE STUDIES;

EID: 84962022982     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv367     Document Type: Article

References (38)

1. Smith DJ, Lapedes AS, de Jong JC, et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004; 305: 371-6
2. Bush RM, Fitch WM, Bender CA, Cox NJ. Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol 1999; 16: 1457-65
3. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25: 6852-62
4. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199: 159-67
5. Russell CA, Jones TC, Barr IG, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008; 26S: D31-4
6. Fonville JM, Wilks SH, James SL, et al. Antibody landscapes after influenza virus infection or vaccination. Science 2014; 346: 996-1000
7. de Jong JC, Smith DJ, Lapedes AS, et al. Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. J Virol 2007; 81: 4315-22
8. Koel BF, van Der Vliet S, Burke DF, et al. Antigenic variation of clade 2.1 H5N1 virus is determined by a few amino acid substitutions immediately adjacent to the receptor binding site. MBio 2014; 5: e01070-14
9. Fouchier RAM, Smith DJ. Use of antigenic cartography in vaccine seed strain selection. Avian Dis 2010; 54: 220-3
10. Bodewes R, de Mutsert G, van Der Klis FRM, et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol 2011; 18: 469-76
11. Irving WL, James DK, Stephenson T, et al. Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG 2000; 107: 1282-9
12. Masurel N, Ophof P, de Jong P. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond) 1981; 87: 201-9
13. Hirst GK. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med 1942; 75: 49-64
14. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-79
15. Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 2014; 6: 1294-316
16. Skehel JJ, Stevens DJ, Daniels RS, et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 1984; 81: 1779-83
17. Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J Virol 2004; 78: 9605-11
18. Blackburne BP, Hay AJ, Goldstein RA. Changing selective pressure during antigenic changes in human influenza H3. PLoS Pathog 2008; 4: e1000058
19. de Jong JC, Rimmelzwaan GF, Bartelds AIM, Wilbrink B, Fouchier RAM, Osterhaus ADME. Het influenzaseizoen 2002/ 03 in Nederland en de vaccinsamenstelling voor het seizoen 2003/ 04. Ned Tijdschr Geneeskd 2003; 147: 1971-5
20. Rimmelzwaan GF, de Jong JC, Bartelds AIM, Wilbrink B, Fouchier RAM, Osterhaus ADME. Het influenzaseizoen 2003/ 04 in Nederland met een beperkte epidemie door de virusvariant A/Fujian, en de vaccinsamenstelling voor het seizoen 2004/ 05. Ned Tijdschr Geneeskd 2004; 148: 1984-8
21. de Jong JC, Rimmelzwaan GF, Bartelds AIM, Meijer A, Fouchier RAM, Osterhaus ADME. Het influenzaseizoen 2004/ 05 in Nederland met de grootste epidemie van de laatste 5 jaar, door virusvariant A/California, en de vaccinsamenstelling voor het seizoen 2005/ 06. Ned Tijdschr Geneeskd 2005; 149: 2355-61
22. Wright PF, Sannella E, Shi JR, Zhu Y, Ikizler MR, Edwards KM. Antibody responses after inactivated influenza vaccine in young children. Pediatr Infect Dis J 2008; 27: 1004-8
23. Wang M, Yuan J, Li T, et al. Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS One 2011; 6: e16809
24. Frank AL, Taber LH, Glezen WP, Paredes A, Couch RB. Reinfection with influenza A (H3N2) virus in young children and their families. J Infect Dis 1979; 140: 829-36
25. Ng S, Fang VJ, Ip DKM, et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis 2013; 208: 1320-4
26. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 1985; 17: 325-35
27. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, coldadapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338: 1405-12
28. Kang EK, Lim JS, Lee JA, Kim DH. Comparison of immune response by virus infection and vaccination to 2009 pandemic influenza A/H1N1 in children. J Korean Med Sci 2013; 28: 274-9
29. Walter EB, Rajagopal S, Zhu Y, Neuzil KM, Fairchok MP, Englund JA. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine 2010; 28: 4376-83
30. Burlington DB, Wright PF, van Wyke KL, Phelan MA, Mayner RE, Murphy BR. Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol 1985; 21: 847-9
31. Verma N, Dimitrova M, Carter DM, et al. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J Virol 2012; 86: 5515-22
32. Lerdsamran H, Pittayawonganon C, Pooruk P, et al. Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population. PLoS One 2011; 6: e16164
33. Slepushkin AN, Ritova VV, Feklisova LV, et al. Results of a two-year study of humoral immunity to influenza A and B viruses in children under the age of 14 years in Moscow and its suburbs. Bull World Health Organ 1984; 62: 75-82
34. Kase T, Morikawa S, Okuno Y, Maeda A, Baba K. Reinfection with antigenically similar influenza virus observed at a pediatric clinic in Osaka from December 1998 to April 2002. Int Congr Ser 2004; 1263: 304-7
35. Mörner A, Bråve A, Kling A-M, et al. Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009. PLoS One 2012; 7: e53511
36. Meijer A, Bosman A, van de Kamp EEHM, Wilbrink B, van Beest Holle MDR, Koopmans M. Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test. J Virol Methods 2006; 132: 113-20
37. Li Y, Myers JL, Bostick DL, et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med 2013; 210: 1493-500
38. Linderman SL, Chambers BS, Zost SJ, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci USA 2014; 111: 15798-803